Bristol Myers Squibb (CELG-RI) Return on Capital Employed Growth (1y) (2012 - 2026)
Bristol Myers Squibb (CELG-RI) Return on Capital Employed Growth (1y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 242.00 |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 660.00 |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | -1,117.00 |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 182.00 |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 464.00 |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -2,391.00 |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -369.00 |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 212.00 |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | 743.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 743.00 |
| Mar 31, 2026 | 479.00 |
| Dec 31, 2025 | 2,564.00 |
| Sep 30, 2025 | 1,648.00 |
| Jun 30, 2025 | 1,281.00 |
| Mar 31, 2025 | 1,209.00 |
| Dec 31, 2024 | -2,904.00 |
| Sep 30, 2024 | -2,348.00 |
| Jun 30, 2024 | -2,199.00 |
| Mar 31, 2024 | -2,184.00 |
| Dec 31, 2023 | 3.00 |
| Sep 30, 2023 | -6.00 |
| Jun 30, 2023 | 40.00 |
| Mar 31, 2023 | 90.00 |
| Dec 31, 2022 | -112.00 |
| Sep 30, 2022 | 1,373.00 |
| Jun 30, 2022 | 1,330.00 |
| Mar 31, 2022 | 1,250.00 |
| Dec 31, 2021 | 1,603.00 |
| Sep 30, 2021 | -902.00 |